

**CORRECTION** **OPEN**

# Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

Sunil S. Patel, David R. Lally, Jason Hsu, Charles C. Wykoff, David Eichenbaum, Jeffrey S. Heier, Glenn J. Jaffe, Keith Westby, Dhaval Desai, Liansheng Zhu and Arshad M. Khanani

© The Author(s) 2023

*Eye* (2023) 37:3705; <https://doi.org/10.1038/s41433-023-02548-2>

Correction to: *Eye* <https://doi.org/10.1038/s41433-023-02497-w>

In the sub-section “Safety analysis,” the percentage 0.6% in the sentence “There was 1 ocular SAE (0.6%; optic ischemic neuropathy) with ACP 2 mg and 1 (1.2%; retinal detachment) with ACP 4 mg” was corrected to 1.5%. In the same section, the percentage in the sentence “One eye (0.6%) in the 2 mg ACP cohort developed intraocular inflammation (IOI) during the study, a case of vitritis, at month 7 without any anterior chamber inflammation” was again corrected to 1.5%. Furthermore, the sentence “The TEAEs were cystoid macular degeneration (4 mg, 1.2%), ischemic optic neuropathy (2 mg, 2.4%), and retinal detachment (4 mg, 1.2%).” was corrected to read “The TEAEs were cystoid macular degeneration (4 mg, 1.2%), ischemic optic neuropathy (2 mg, 1.5%), and retinal detachment (4 mg, 1.2%)”. Finally, the footnote of Supplementary Table 4 was corrected from “Based on a mixed-effects model for repeated measures assuming a piecewise linear trend in time with knots at Month 6, Month 12, and Month 18” to “Based on a mixed-effects model for repeated

measures assuming a piecewise linear trend in between times: 0 to Month 6, Month 6 to Month 12, and Month 12 to Month 18”. The original article has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023